• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Strong Earnings Might Change The Case For Investing In Indivior Pharmaceuticals Stock (SPUN)

    Simply Wall St·11/03/2026 14:24:22
    Listen to the news
    • Indivior Pharmaceuticals reported third quarter 2026 sales of US$356 million and net income of US$137 million, with higher basic and diluted earnings per share from continuing operations than the same period a year earlier. The company also provided nine month figures that were above the prior year levels.
    • The firm reaffirmed its full year 2026 net revenue outlook of US$1.295b to US$1.365b. This reflects management confidence in the current demand profile and cost execution associated with these recent earnings results.
    • The focus now turns to how Indivior Pharmaceuticals' reaffirmed 2026 revenue guidance could influence the broader investment narrative around the business.

    Scan how Indivior Pharmaceuticals fits alongside other earnings driven stories by reviewing our curated list of 19 high quality undiscovered gems with strong fundamentals that may still be flying under the radar.

    What Is Indivior Pharmaceuticals' Investment Narrative?

    To own Indivior Pharmaceuticals, you have to buy into a fairly concentrated story. The business is tightly focused on opioid use disorder treatments, anchored by SUBLOCADE and SUBOXONE, and the latest quarter shows that this focus currently supports US$356 million in quarterly sales and US$137 million in profit. The reaffirmed 2026 net revenue range of US$1.295b to US$1.365b signals that management sees current demand patterns and pricing as consistent with how the year has played out so far.

    The short term hinges on execution in that core OUD franchise, keeping monthly injections and film products on formulary and in front of prescribers, while funding R&D on INDV-2000 and INDV-6001 without stretching the balance sheet further. Earnings and cash flow quality look solid, yet the flagged issues around debt coverage and negative shareholders equity mean the strong recent results and price gains over 1 year sit alongside a capital structure that still needs watching.

    That said, the picture shifts once you weigh those robust profits against the one balance sheet issue that keeps coming up...

    There's only one way to know the right time to buy, sell or hold Indivior Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Indivior Pharmaceuticals's Fair Value.

    NasdaqGS:SPUN 1-Year Stock Price Chart
    NasdaqGS:SPUN 1-Year Stock Price Chart

    Exploring Other Perspectives

    Four fair value estimates from the Simply Wall St Community span roughly US$49.5 to about US$165, with opinions spread across the full set of buckets. That is a wide gap. Before the October 29 earnings and reaffirmed 2026 revenue outlook, those views already differed. Use this spread to compare how you see Indivior Pharmaceuticals and to explore several alternative viewpoints.

    Explore 3 other Indivior Pharmaceuticals fair value estimates, including one that suggests it could be worth just $49.50!

    Decide For Yourself

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Indivior Pharmaceuticals?

    Once you have formed a view on Indivior Pharmaceuticals, it can help to widen the lens and compare it with other businesses that share similar qualities or offer very different risk and reward profiles. The Simply Wall St Screener lets you do that side by side in minutes.